Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?

Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?

Background: This study was designed to evaluate the differential effect of epidermal growth factor receptor (EGFR) mutation status (exon 19 vs. 21) on progression-free survival (PFS) and overall survival (OS) in treatment-naïve advanced EGFR mutation-positive nonsmall cell lung cancer (NSCLC) treate...

Full description

Bibliographic Details
Main Authors: Amit Joshi, Vijay Patil, Vanita Noronha, Anuradha Chougule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2018-01-01
Series:Lung India
Subjects:
Epidermal growth factor receptor mutation
exon 19
exon 21
gefitinib
nonsmall cell lung cancer
palliative
Online Access:http://www.lungindia.com/article.asp?issn=0970-2113;year=2018;volume=35;issue=1;spage=27;epage=30;aulast=Joshi

Internet

http://www.lungindia.com/article.asp?issn=0970-2113;year=2018;volume=35;issue=1;spage=27;epage=30;aulast=Joshi

Similar Items